The results of the current study support that PCSK9-LDL binding analysis should also be included for assessment of potential FH-associated gene mutations in PCSK9 and APOB that do not affect the respective LDLR interactions. The gene discussed is PCSK9; the disease is familial hyperaldosteronism.